|
The Board of Henderson Morley plc (“Henderson Morley” or “the Company”), the AIM quoted drug discovery company, announces its final results for the year to 30 April 2009.
HIGHLIGHTS
- First revenues from vaccine against Eel Herpes virus (EHV) will be received during the next eel fishing season which runs from November to April.
- In discussions with commercial partners to out-license Feline Herpes Virus (“FHV”) development candidate and Canine Cancer Immunotherapy.
- The Company currently has 47 granted patents with 45 pending.
- Losses before tax fell to £1,103,106
- Revenues grew to £80,019
POST PERIOD EVENTS
- Successfully raised £625,000 via an Open Offer.
- Grant application submitted to the US government funded National Institute of Health. This could secure non-dilutive funding to further develop the Cytomegalovirus (“CMV”) Vaccine.
- Koi Herpes Virus (“KHV “) vaccine field study has produced positive results.
- Discussions continuing regarding the divestment of ICVT.
- Commenting on today’s results, Executive Chairman, Andrew Knight said: “Our long term strategy remains on consolidating as a pure play vaccine company by 2011. We believe that this is a period of great opportunity for Henderson Morley, as we continue to work on building shareholder value through divestment as well as licensing and collaboration.”
Please click here to download the entire results in pdf format.
|
